Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Outlook Therapeutics (OTLK) Other Non Operating Income (2017 - 2022)

Outlook Therapeutics has reported Other Non Operating Income over the past 3 years, most recently at $6.2 million for Q2 2020.

  • Quarterly Other Non Operating Income rose 1554.92% to $6.2 million in Q2 2020 from the year-ago period, while the trailing twelve-month figure was -$1.9 million through Jun 2020, down 212.28% year-over-year, with the annual reading at -$577659.0 for FY2023, 43.67% up from the prior year.
  • Other Non Operating Income was $6.2 million for Q2 2020 at Outlook Therapeutics, up from -$8.1 million in the prior quarter.
  • Over five years, Other Non Operating Income peaked at $6.2 million in Q2 2020 and troughed at -$8.1 million in Q4 2019.
  • The 3-year median for Other Non Operating Income is -$423686.0 (2019), against an average of -$751177.8.
  • The largest YoY upside for Other Non Operating Income was 1554.92% in 2020 against a maximum downside of 1554.92% in 2020.
  • A 3-year view of Other Non Operating Income shows it stood at -$1.3 million in 2017, then crashed by 543.63% to -$8.1 million in 2019, then skyrocketed by 176.47% to $6.2 million in 2020.
  • Per Business Quant, the three most recent readings for OTLK's Other Non Operating Income are $6.2 million (Q2 2020), -$8.1 million (Q4 2019), and -$423686.0 (Q2 2019).